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Abstract: 
Fullerenes are carbon spheres presently being pursued globally for a wide range of applications 
in nanomedicine. These molecules have unique electronic properties that make them attractive 
candidates for diagnostic, therapeutic and theranostic applications. Herein, the latest research is 
discussed on developing fullerene-based therapeutics as antioxidants for inflammatory diseases, 
their potential as antiviral/bacterial agents, utility as a drug delivery device and the promise of 
endohedral fullerenes as new MRI contrast agents. The recent discovery that certain fullerene 
derivatives can stabilize immune effector cells to prevent or inhibit the release of 
proinflammatory mediators makes them potential candidates for several diseases such as asthma, 
arthritis and multiple sclerosis. Gadolinium-containing endohedral fullerenes are being pursued 
as diagnostic MRI contrast agents for several diseases. Finally, a new class of fullerene-based 
theranostics has been developed, which combine therapeutic and diagnostic capabilities to 
specifically detect and kill cancer cells. 
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Article: 
Fullerenes as a platform for new solutions in several medicinal areas 
Empty cage fullerenes (Figure 1A & B) have unique electrochemical properties and have a wide 
range of potentially beneficial biologic properties. Another type of fullerene can have metals 
enclosed inside them (Figure 1C). Fullerenes have a unique cage structure with delocalized &pi;-
molecular orbital electrons. This structure confers unusual activity in electron transfer systems 
due to their low reorganization energy, low lying excited states (singlet and triplet) and extended 
triplet lifetimes. Furthermore, the spherical configuration of the planar benzene rings imposes an 
unusual constraint on these &pi;-electron orbitals. The native fullerene cage is insoluble in water 
and must be derivatized (simply meaning moieties or side groups must be added to 
the carbon cage) in order to make them water soluble (compatible in biological systems). The 
ability of fullerenes to be derivatized with side chains provides opportunities to diversify, 
manipulate and harness the electronic properties of the cage for selected applications. Of course, 
each derivation results in changes of the compound's physical and chemical properties, including 
particle size/length, &zeta;-potential, molecular weight, surface characteristics and solubility, 
contributing to how they affect biological systems. All too often, results from studies examining 
the effects of fullerenes on biological systems tend to be extrapolated to other applications. As 
demonstrated below, each fullerene derivative (FD) must be assessed separately depending on 
the biological application. Even extremely similar FDs can have completely opposite results, 
which stimulates efforts to understand how changing the chemical composition and structural 
arrangement of fullerenes affects molecular interactions at the cellular, tissue and organ system 
levels. Consequently, their inherent properties described in the article, combined with their 
ability to be derivatized with side chains, results in almost limitless new chemical structures, 
making them ideal platform molecules for innovative new solutions to basic biological problems. 
Fullerenes are one of many types of carbon nanomaterials being investigated for next-generation 
medical applications; presently carbon nanotubes are being investigated as drug carriers 
(manipulating their hollow internal core), biosensensors (attaching enzymes to their walls) and 
targeted transporters of drugs [1-4] . The 2D structure graphene is being investigated as a 
drug/gene delivery nanocarrier and targeted cancer therapy [5,6] . This article will focus on the 
applications of both empty cage derivatized and endohedral fullerenes for therapeutic, diagnostic 
and theranostic (combination of diagnostic and therapeutic) applications. 
Fullerenes as therapeutics 
Fullerenes have been coined 'free radical sponges' and described most frequently as antioxidants, 
although in biological systems they can paradoxically act as both oxidants and antioxidants. The 
generation of free radicals such as reactive oxygen species (ROS) and reactive nitrogen species 
occurs naturally in cells, and their presence at sites of disease pathologies suggests they 
contribute to disease progression. The term free radical refers to a molecular species that 
possesses an unpaired electron, which makes them highly reactive. Many of the more common 
ROS or reactive nitrogen species that contribute to oxidative or nitrosative stress in biological 
systems are free radicals, including hydroxyl radicals (OH*), superoxide anions (O 2 - ), and 
peroxynitrites (ONOO- ). Other ROS are not free radicals, including singlet oxygen and 
hydrogen peroxide (H2 O2 ), which are considered ROS because they can generate oxygen 
radicals, such as superoxide, via the Fenton reaction. These ROS can react with, crosslink and 
alter the function of many macromolecules. These species can negatively affect a wide variety of 
biological processes; however, in certain situations they can be beneficial to some biological 
processes such as signaling and cellular defenses. Antioxidants (e.g., vitamins A and C) are 
molecules that can eliminate or neutralize free radical electrons. This has led to a tremendous 
amount of research on preventing damage using antioxidants, theorized to, in turn, counteract 
disease pathologies. Indeed the perceived benefits of antioxidants are a widely accepted concept 
yet their use has been mainly centered on over-the-counter supplements for general health and 
antiaging benefits. 
The carbon cage (usually C60 and C70 ) of empty cage fullerenes (Figure 1) can have antioxidant 
functionality based on its ability to absorb electrons and disperse them through the 3D &pi;-
conjugated structure distributed over its surface. This ability to scavenge free radicals has led to 
their potential as a new way for treating a wide range of diseases and pathologies; these include 
multiple sclerosis (MS) [7] , neurodegenerative [8] , anti-HIV activity [9,10] , cancer [11] , radiation 
exposure [12] , ischemia [13] , osteoporosis [14] , general inflammation [15] and selective 
antimicrobial agents against bacteria [16] . Interestingly, mice and rats chronically treated with 
water-solubilized carboxylated fullerenes have significantly extended lifespans compared with 
littermate controls [17,18] . There are almost endless possibilities for adding side groups to the 
carbon cage to induce functionality, resulting in potential answers to some of modern medicine's 
most elusive problems. 
* Fullerenes as carriers for drug & gene delivery 
Recently, much interest and focus has been directed towards developing safe, targeted and 
competent transport mechanisms for drugs and genes to cells. This transport is often riddled with 
difficulties as the cellular membrane creates efficient barriers that can prevent or slow the uptake 
of compounds. However, the small size (<5 nm) of fullerenes has generated significant interest in 
the field. Hydrophillic entities can be decorated around the fullerene cage, modifying the 
fullerenes relative insolubility in aqueous solutions. The water-soluble FD can readily cross the 
cellular membrane without damaging cells [8,19] . These fullerenes can be further modified to 
become carriers of drugs and genes. Evaluated below is some of the present research in which 
fullerenes have been functionalized to become water soluble and utilized as versatile 
nanocarriers to target, treat and prevent disease with high biocompatibility. 
* Ability of fullerenes to affect mast cell-driven allergic inflammation 
Allergic reactions are the result of B-cell-produced, specific IgE antibody to common, normally 
innocuous antigens. In simplistic terms, mast cells (MCs), peripheral blood basophils (PBBs), 
natural killer cells, T cells and even B cells are responsible for driving the initial allergen-
inducing reaction through the production of IL-4 and other Th2-specific cytokines, which result 
in IgE sensitization. Re-exposure to the allergen triggers an allergic response through the release 
of inflammatory mediators from MCs and PBBs. The IgE produced binds to Fc&epsilon;RI on 
MCs and PBBs, and the release of preallergic mediators is induced when two or more IgE 
molecules are crosslinked with the allergen. Indeed, most allergy medications are aimed at 
neutralizing (antihistamines and H1 -receptor blockers) or preventing (omalizumab) MC and 
PBB Fc&epsilon;RI responses. New research has demonstrated that specifically engineered FDs 
are taken up and can stabilize human tissue MCs, preventing the release of proinflammatory 
mediators from these cells, making them ideal candidates for those diseases controlled by MC 
mediators [20-22] . The ability for FDs to stabilize MC-driven diseases in vitro should translate to 
blocking in vivo, as shown by Dellinger et al.[21] . 
* Ability of fullerenes to dampen asthma pathogenesis 
MCs are ubiquitously expressed in tissues and are uniquely able to initiate and propagate certain 
inflammatory responses, as well as offer an interface between innate and adaptive immunity [23] . 
Mice without MCs fail to develop asthma-like pulmonary disease when sensitized with less 
aggressive immunization protocols and challenged with aerosolized allergens [24,25] . However, 
the strongest evidence that MCs are critical for human asthma comes from the many therapeutics 
used to treat the disease in humans. In general, two categories of therapies were developed to 
control asthma; blocking MC activation before it occurs (stabilizers) and blocking MC activation 
after it occurs. MCs are the only cells in the lung that have prestored TNF-[alpha] in their 
granules that can be immediately released upon allergen provocation [26] and blockade of this 
cytokine is a valid target currently being investigated [27] . Therapies that block the effects of 
MCs after activation occurs are well known, commonly used, and include antihistamines and 
H1 -receptor blockers. Thus, the importance of MCs in asthma pathogenesis is well established, 
and controlling the amount of mediator release from these cells is a proven drug development 
strategy. 
The role of basophils in asthma is less clear. Their role in allergic disease has largely been 
viewed as redundant to that of tissue MCs. This line of thought, however, is changing with 
evidence that has emerged during the last 15 years. These cells are a significant source of the 
cytokines IL-4 and IL-13, both of which are vital to the pathogenesis of allergic disease, 
including asthma. It has been demonstrated that increased levels of basophils were present in the 
lungs of deceased asthmatics using a basophil-specific antibody developed for immunologically 
detecting these cell types [28,29] . Thus, the infiltration of basophils into allergic lesion sites has 
sparked greater interest in this once overlooked immune cell, both in adaptive as well as innate 
immunity [30] . 
There is a strong need for novel therapeutics to treat asthmatic disease; indeed up to 55% of 
patients receiving treatment for asthma have uncontrolled symptomology [31] . In some situations, 
especially in less severe asthmatics, asthma control is achieved with the use of nonspecific anti-
inflammatories, such as corticosteroids, or by the use of antihistamines and leukotriene 
inhibitors. However, these therapies are generally less effective in severe asthmatics or in 
patients with steroid resistance. As shown below, FDs are able to suppress both disease onset and 
reverse established disease in murine asthma models. The latter is especially important as human 
asthma treatment always involves established disease. 
The utility of FD's role in asthma prevention and reversal can be validated in mice treated with 
FDs throughout ovalbumin challenge. Treated animals have significantly less airway 
inflammation and bronchoconstriction compared with untreated animals. In fact, total 
inflammation and bronchoconstriction in the tetraglycolic acid FD-treated animals are not only 
significantly reduced, but are similar to that seen in nonsensitized controls (Figure 2) [32] . Thus, 
symptoms of disease are largely reversed in these animals. These studies used a model 
previously shown to utilize MCs [25] . In the established disease model, where mice were treated 
throughout disease development, FDs dampened eosinophilia and cytokine levels significantly in 
the bronchoalveolar lavage (BAL) fluid. Lung sections show massive cellular infiltration in 
untreated animals, while those receiving FDs have minimal cellular infiltration surrounding the 
airways (Figure 3). This led to reduced airway hyper-responsiveness in FD-treated animals. 
Thus, FDs may be useful in a clinical setting to reverse asthma pathogenesis and limit 
exacerbation of symptoms. 
While previously published in vitro studies suggested that MC inhibition may be the 
predominant mechanism of FD inhibition [20,22] , in vivostudies suggest multipotent effects of 
these unique compounds. FD treatment reduces the levels of BAL Th2 proinflammatory 
cytokines and reduces lung inflammation. While IL-4 stimulates IgE production by B cells, IL-5 
both recruits and activates eosinophils at the site of inflammation. FD treatment significantly 
reduces both IL-4 and IL-5 in the BAL fluid. Additionally, serum IgE levels were significantly 
reduced following FD treatment. 
Importantly, the use of FD revealed a novel mechanism of action and opened up new avenues of 
research for asthma. Several eicosanoids (EETs) derived from the CYP450 pathway are 
relatively stable, and these molecules were measured in BAL fluid samples using mass 
spectrometry. The EETs are consistently associated with relaxation of the bronchi and other in 
vivo anti-inflammatory actions [33,34] . The epoxyeicosatrienoic acid was consistently upregulated 
in BAL fluid from FD-treated mice (Figure 4). Further in vivo studies demonstrated that the 
EETs play a major role in dampening the asthma phenotype as inhibitors of the EETs prevented 
the FD-induced modulation of the ovalbumin-induced asthma model [32] . Certain EETs stabilize 
human lung MCs through the inhibition of Fc&epsilon;RI-mediator release and upregulate 
the CYP1B1 gene in these cells (Figure 4). Thought to be produced by lung epithelial and 
endothelial cells, the EETs have been shown to relax histamine-precontracted guinea pig and 
human bronchi [35,36] . Furthermore, they can inhibit the upregulation of VCAM-1, E-selectin, and 
ICAM-1, thus, potentially limiting cellular infiltration of the lung [37] . Consequently, 
epoxyeicosatrienoic acid upregulation plays a significant role in dampening airway inflammation 
and bronchoconstriction in these models. FD upregulation of EETs is a novel mechanism for 
controlling asthma and suggests that strategies that induce the production of EETs may be a 
viable therapeutic strategy for treating asthmatics. 
The efficacy of FD for the treatment of asthma is illustrated through a mechanism involving the 
dampening of eosinophilia and cytokine levels, reducing airway hyper-responsiveness and 
upregulating EETs. Thus, FD compounds have the potential to become novel therapeutics for the 
treatment of asthma and pave the way for new research efforts focusing on the role of EETs in 
human disease. 
* Fullerenes inhibit inflammation caused by arthritis 
MCs play a critical role in the pathogenesis of synovitis in a murine model of rheumatoid 
arthritis (RA) [38,39] . The synovium of patients with RA is chronically inflamed and characterized 
by an expanded population of MCs, as in the mouse model. MCs are markedly increased in 
number and can constitute [greater than or equal]5% of the expanded population of total synovial 
cells. The number of accumulated MCs differs substantially from patient to patient, in general, 
varying directly with the intensity of joint inflammation [40-42] . MC mediators (histamine and 
tryptase) are also present at higher concentrations in the synovial fluid of inflamed human 
joints [43] . 
MC degranulation has long been associated with arthritis in several animal models, but a critical 
functional role in the disease was established in the K/BxN mouse model [39,44] . This arthritis 
model closely mimics human RA via symmetric joint involvement, chronicity, a distal-to-
proximal gradient of joint involvement and histological features, including synovial infiltrates, 
pannus, and erosions of cartilage and bone [45] . Mice deficient in MCs are highly resistant to 
arthritis, whereas reconstitution with normal MCs restores the wild-type phenotype. 
Furthermore, degranulation of MCs in the synovium is the first event observed histologically, 
occurring within 1-2 h of administration of K/BxN serum [46] . Recent studies reaffirmed a role 
for MC mediators in arthritis [38] . Thus, MCs are a normal cell population within the human 
synovium and have a critical role in the pathogenesis of inflammatory arthritis. 
The mitochondrial electron transport chain is the machinery that orchestrates one of the most 
fundamental chemical processes; the generation of cellular energy from oxygen resulting in the 
fuel that supports all eukaryotic life. However, it is a highly sensitive process and, when 
unbalanced, leads to the generation of free radicals or ROS, which have been proposed as being 
the mechanism underlying many chronic human diseases, including MC activation and 
inflammatory arthritis [47] . Fullerenes can be specifically designed to target and accumulate in 
the internal mitochondrial membrane bilayers. Once incorporated, FDs are positioned to 
neutralize superoxide molecules, reactive lipid radicals and radicals that have formed on 
transmembrane proteins at the site where they are generated, thus, inhibiting 
inflammation [15,21,48] . This, in turn, is predicted to impact diseases whose pathologies stem from 
radical injury. 
Therefore, rationally designed FDs were synthesized to significantly block ROS 
production [32,49] . While it has been shown previously that human MC degranulation in response 
to Fc&epsilon;RI stimulation involves ROS [46] , it is not clear whether blocking ROS directly 
blocks degranulation and cytokine production. However, results suggest that blocking ROS using 
FDs in response to an immune complex (a Fc&epsilon;RIIA-dependent stimuli [50] ) parallels 
inhibition of mediator release. This is in line with previous work suggesting that FDs interfere 
with the generation of mitochondrial-derived ROS [51,52] . 
To investigate the ability of FDs to inhibit arthritis, the K/BxN serum transfer model was used. 
This model induces a rapid and severe synovitis, similar to human RA, which is dependent on 
neutrophils, MCs and macrophages. Its MC dependence was revealed from studies in which two 
strains of mice deficient in this cell type, W/Wv and Sl/Sld, were resistant to disease induction 
following serum transfer [44] . Susceptibility to the disease is restored in the W/Wv strain by MC 
engraftment. Thus, in the K/BxN model, MCs function as a link between the serum transfer 
induction of autoantibodies, soluble mediators and other effector populations. By contrast, MC-
deficient mice are still susceptible to collagen-induced arthritis [53] as well as anticollagen 
antibody/lipopolysaccharide-induced arthritis [45] . 
Previously published results have demonstrated the ability of FDs to inhibit MC-
mediated [20,22] and general inflammation [15] . Given that MCs are the cellular link leading to 
inflammatory arthritis induction and progression, it has been hypothesized that blocking MC 
mediator release could block inflammatory arthritis. The liposome-encapsulated FD amphiphilic 
liposomal malonylfullerene (Figure 5) was administered intraperitonealy before disease 
induction using the K/BxN model [44] , and during the course of disease onset there was a striking 
inhibition of the K/BxN-induced disease pathology. After K/BxN serum transfer, the serum-
treated mice demonstrated typical synovial hyperplasia, pannus formation and inflammatory 
infiltrates (Figure 6A). By contrast, amphiphilic liposomal malonylfullerene-treated animals had 
less evidence of clinical joint inflammation (Figure 6B) comparable to nondiseased animals 
(Figure 6C). 
* Fullerenes as a potential therapy for MS 
Experimental allergic encephalomyelitis (EAE) is a rodent model of human MS characterized by 
inflammation in the CNS [54] . Similar to human MS, EAE is associated with an early breach of 
the blood-brain barrier (BBB), focal perivascular mononuclear cell infiltrates and demyelination 
leading to paralysis of the extremities. While CD4 + T cells have been implicated, the underlying 
cause of increased vascular permeability that facilitates the entry of T cells into the CNS is 
unknown. 
MC contribution to the pathogenesis of MS has been hypothesized based on their presence in 
CNS plaques of MS patients and the correlation between the number, distribution or MC markers 
in MS or EAE pathology [55] . Further evidence for MC involvement in EAE/MS came from 
studies using MC-deficient mice [56] . The MC-deficient W/Wv mice exhibited significantly 
reduced disease incidence, delayed disease onset and decreased mean clinical scores when 
compared with their wild-type congenic littermates. No differences were observed in the T- and 
B-cell responses between the two groups, and reconstitution of the MC population in W/Wv 
mice restores induction of early and severe disease to wild-type levels. These data provide a new 
mechanism for immune destruction in EAE and indicate that MCs may be sentinels of neurologic 
inflammation. 
Previous studies have demonstrated that fullerene-based therapeutics can significantly ameliorate 
EAE [7] . The FD protected neurons from oxidative and glutamate-induced injury, and restored 
glutamine synthesis and glutamate transporter expression in astrocytes under inflammatory 
insult. The in vitro efficacy translated into in vivo efficacy, as treatment initiated after disease 
onset reduced the clinical progression of chronic EAE in mice, suggesting this may be useful in 
the treatment of progressive MS and other neurodegenerative diseases. 
A fullerene-based MS therapeutic was designed to specifically target axonal cells. Here a MC-
stabilizing FD was conjugated with tropine and an IR800 dye for tracking [22] . This MC-
stabilizing compound is targeted to neurons based on the affinity of tropine (a derivative of 
tropane containing an oxygen atom) for neuronal cell dopamine transporter receptors [57] . Thus, 
in addition to its ability to inhibit MC-mediator release, this compound is theorized to also target 
neurons and scavenge ROS. To determine if this MC-stabilizing, neuron-targeting, IR800 dye 
fullerene molecule could cross the BBB, mice were injected intravenously with fullerene dye, 
and imaged immediately and at several time points. 
Initial experiments show the fullerene-dye conjugate can cross the BBB and be deposited in the 
brain (Figure 7). This approach using basic chemistry to add a variety of axon/neuron-targeting 
motifs with varying ratios of targeting motif to the fullerene core is now being used to foster 
maximal cell targeting and uptake. These results confirm previous studies using a C 60 -based 
formulation suggesting FDs can cross the BBB. First, mice orally treated with FDs have reduced 
superoxide generation in the brain [58] . Second, FDs given orally can reverse age-related changes 
in mitochondrial electron transport function and block age-related increases in superoxide 
produced by mitochondria taken from the brain [17,59] . 
The SH-SY5Y human neuroblastoma cells express dopamine transporters and were 
differentiated into nondividing neurons using a protocol described previously [60] . A Texas 
Red® (Life Technologies, CA, USA)-conjugated, fullerene-tropane derivative clearly recognized 
the neuronal dopamine transporter receptors (Figure 8B). This is evident by the accumulation of 
clusters of red (from the Texas Red dye) on the membrane of the neurons and also staining of the 
neuronal axon. Interestingly, it appears there is an abundance of fullerene-tropane at the newly 
formed part of the axon (closest to the cell core) but not towards the outer axon sheath. 
Fullerene-tropane also penetrates into cells where there is evidence of mitochondrial 
colocalization (Figure 8B). 
MCs are important regulators of MS [54-56] . Oxidative stress, through the generation of ROS, is 
an underlying mechanism that mediates MC signaling and MS pathology [61] . Indeed, several 
antioxidants are currently in various phases of human clinical trials (i.e., lipoic acid, inosine and 
Triomar® [Pronova Biocare, Oslo, Norway], see [201] ). Given that FDs can stabilize MCs [22] , are 
potent antioxidants [49,62] and are anti-inflammatory medications [15,48] , FDs were tested for their 
ability to inhibit EAE. As seen in Figure 9, FDs reduce the clinical scores associated with MS in 
the EAE model, suggesting this class of rationally designed compounds may be used as a 
platform for new areas of therapeutic research for MS. 
Fullerenes as diagnostics 
Carriers for diagnostics have shown great potential in solving many present day medical imaging 
limitations. Endohedral fullerenes consist of a hollow core carbon shell, which during synthesis 
is capable of encapsulating metal ions within the cage. The endohedral fullerene cage is typically 
larger than the common C60 . This is due to size constraints imposed by the small size of the 
C 60 molecule; therefore, C80 molecules (or even higher: C82 , C84 , C86 , C88 and C2n ; i.e., n = 12, 
13, 14 and so on) accommodate sufficient enclosure of desired metals, including lanthanum, 
yttrium, scandium and gadolinium. The endohedral fullerene's strong electronic properties can 
strongly enhance diagnostics. Such compounds are currently being investigated as a platform to 
detect cancer [63] , atherosclerosis [64] and arthritis [65] . Present day diagnostic limitations of both 
sensitivity and specificity have stalled progress on accurate, enhanced patient imaging. Thus, 
metal endohedral fullerenes have the potential to affect the diagnosis of numerous other 
diagnostic pathologies. 
One class of endohedral fullerene is typified by Trimetaspheres® (TMS; Luna Innovations 
Incorporated, VA, USA), which are C80 based with gadolinium enclosed within the cage (Figure 
1C). One field in which they are being investigated for use is in MRI - a widely used diagnostic 
procedure that utilizes gadolinium-based contrast agents (i.e., Magnevist[trademark]; Bayer 
HealthCare Pharmaceuticals Inc., NJ, USA). However, several issues have limited gadolinium 
chelate-based contrast agents (i.e., Magnevist) for use as image-guided interventions with MRI, 
including gadolinium toxicity [66-69] , rapid clearance from the body, poor relaxivity-dependent 
sensitivity and inability to be targeted to disease-specific biomarkers. The TMSs solve many of 
the problems associated with current gadolinium-based contrast agents. First, the gadolinium 
(inside cage) that is toxic at sufficient concentrations is separated from active targeting moieties 
(outside cage) by an extremely stable carbon shell, possibly increasing safety. Unlike current 
chelates, adding targeting ligands/moieties to TMSs does not affect the ability of gadolinium to 
become free of the compound. Second, gadolinium-encapsulated endohedral fullerenes are more 
sensitive. Targeted imaging agents require strong signals by which to report the presence of an 
agent at a particular location. The TMS achieves 25- to 50-fold greater relaxivity compared with 
traditional gadolinium contrast agents. Third, the fullerene cage can be targeted to disease 
biomarkers, as targeting moieties can be attached to the cage (including empty cage fullerenes). 
Finally, the TMSs appear to be safe; no toxicity was detected in vitroand in vivo [49,70] , although 
further studies to assess their safety are clearly needed. 
The crux of the TMS platform for diagnosis utilizes specific biomarkers conjugated to the 
gadolinium-encapsulated endohedral fullerene MRI contrast agents and, in theory, could be used 
for any disease for which specific expression of suitable receptors exist. Two disease processes 
evaluated, atherosclerosis and glioblastoma, possess disease-specific biomarkers that can be 
targeted. Based on working prototypes, TMS endohedral fullerenes have been developed to study 
their cellular uptake by macrophage foam cells (for atherosclerosis) and glioblastoma cells (for 
cancer) in vitro . This prototype takes advantage of already identified biomarkers on diseased 
cells, followed by chemically attaching ligands to target the TMS to these cells (characterizing 
the molecules), and use of in vitro assays to determine if they bind to and enter the cells and 
assess any toxicological effects. 
* Endohedral fullerene MRI contrast agents as diagnostics for atherosclerotic plaque 
Atherosclerosis is an inflammatory disease representing a major healthcare problem in the USA. 
Initiation of atherosclerosis begins when blood cells (monocytes) 'stick' to blood vessel walls as a 
result of an individual's increased cholesterol consumption. Over time the cells continue to 
accumulate on vessel walls and engulf the fat droplets until large structures called plaques begin 
to form. The plaque can rupture and lead to complete blockage of blood flow through the vessels 
involved, leading to a heart attack and/or stroke. To be able to noninvasively determine the 
extent of plaque build up in vessel walls of at risk patients using already established diagnostic 
procedures would facilitate treatment options that could greatly reduce myocardial infarction and 
stroke incidence, which represent the most frequent causes of death in western society. 
While several molecules have already been identified that are selectively expressed or highly 
upregulated on plaque lesions [71-73] , preliminary findings in the field focus on CD36 
(macrophage scavenger receptor) as a potential target receptor. The CD36 receptor is involved in 
foam cell formation, mediating the influx of lipids into macrophages, possessing a promiscuous 
ligand binding and is highly expressed on lipid-laden macrophages of human atherosclerotic 
aorta [74-77] . Different forms of oxidized phosphatidylcholine and oxidized low-density 
lipoprotein are high affinity ligands for CD36 [78] . The basic structure of the compounds consists 
of the TMS enclosed within liposomes, which was previously demonstrated [48] , with CD36 
ligands decorated on the liposomes (Figure 10). As seen in Figure 11, APOE knockout 
mice [79]were used to test the atherosclerotic plaque-targeting contrast agent, which serves as a 
working prototype for a new class of diagnostic agents that specifically attach to atherosclerotic 
plaques, so that previously undetected lesions can be diagnosed using MRI. The atherosclerotic 
plaque-targeting contrast agent clearly reveals plaque accumulation by MRI that is not seen 
using the same molecule without targeting ligands. 
Fullerenes as theranostics 
Multifunctional approaches that incorporate both medical imaging and therapy could be the 
future of medicine, and fullerenes prove to be an attractive platform for these approaches. This is 
due to the fullerene's ability to simultaneously detect (with biomarkers), image (with gadolinium-
based contrast) and deliver a therapeutic payload to a specified site. Progression can be 
monitored in real time to assess the effectiveness of treatment using direct visualization of the 
areas of interest through the high-contrast capabilities of endohedral fullerenes. Nanoparticles are 
presently being pursued for imaging and diagnostic applications [80,81] and the next logical leap 
would be to couple this with patient therapy. Such multifunctional nanoplatform-based probes 
have shown to be effective in mouse models, including tumor detection and treatment [82-84] , as 
well as atherosclerosis and arthritis [85-87] . 
* Endohedral fullerene MRI contrast agents as theranostics for brain cancer 
Glioblastoma multiforme is an aggressive high-grade brain tumor with a poor prognosis. Ideally, 
a multifunctional nanoscale compound is needed that can simultaneously diagnose tumor 
progression and can also specifically target and kill the tumor. IL-13 receptors are selectively 
expressed on astrocytoma cells in gliomas. It has been previously reported that IL-13 receptor-
targeted chemotherapies (diphtheria toxin)[88,89] delivered through lipid nanovesicles (liposomes) 
were effective in targeting and shrinking glioma tumors in a subcutaneous tumor model. MRI 
using gadolinium-based contrast agents has been used for diagnosing glioblastoma. IL-13 
receptors are expressed on glioblastoma multiforme cells and are not significantly expressed in 
normal tissue [90] . In fact, many clinical trials are underway using IL-13 as a targeting moiety for 
various interventions of the disease [201] . 
TMS was used as a platform for developing novel glioblastoma-targeting theranostics in which 
the diagnostic TMS is enclosed within glioblastoma-targeting IL-13 liposomes that can deliver a 
therapeutic payload of doxorubicin (Figure 12). After verifying in vitro binding of the 
glioblastoma-targeting theranostics to human glioblastoma cells, the nanoparticles were tested in 
vivo . As seen in Figure 13, the glioblastoma theranostic can target and shrink human brain 
tumors that have been transplanted in mice. 
Fullerene toxicity: is there concern? 
Of course, toxicity considerations are implicit when contemplating human use for novel 
compounds such as fullerenes. To this end there have been a number of studies examining the 
toxicity using a myriad of fullerene preparations. However, the results of most of these studies 
are conflicting, inconclusive and the subject of much debate. One such fullerene study (which 
was subsequently proven to be unfounded) exposed juvenile bass to nonderivatized C60 , which 
is insoluble in water [91] . Unfortunately the authors did not include a control that provided 
insights into whether the observed effects were simply due to large aggregated particles, 
tetrahydrofuran contaminants or whether they were specific to the chemical nature of C60 . 
However, there was widespread publicity that concluded fullerenes as a class of compounds 
could be toxic [92] . A subsequent publication by the same group (without publicity) demonstrated 
that the originally observed 'toxicity' was due to impurities in the sample [93] . Even more recently 
these original studies were formally addressed by a follow-up publication, which stated that the 
original Oberdorster study was 'compromised by experimental artifacts' [94] . On the opposite end 
of the spectrum, studies in mice demonstrate that similar C60 preparations significantly increase 
the lifespan of mice [17] and rats [18] . Thus, it is difficult for researchers, and the general public, to 
determine if fullerenes are dangerous nanostructures that should be banned or a potential novel 
platform for developing new medicines. The answer to explain how a class of compounds can be 
simultaneously toxic and lifespan extenders will rely on well-controlled structure-activity 
studies. 
Contributing to the confusion is that few studies examining toxicity use well characterized and 
highly purified material; those that are not mixtures of many isomers, aggregate sizes and 
impurities. Most studies in which fullerenes are deemed to be toxic use starting material with 
little or no characterization (e.g., dynamic light scattering, &zeta;-potential and Fourier 
transform infrared spectroscopy). In addition, no studies have compared differences in cage sizes 
(C60 vs C70 vs C80 ); the latter two are much more likely to become US FDA-approved products 
owing to their size being conducive to fewer numbers of isomers when adding side-chain 
moieties. The FDA requires that every new chemical entity must be evaluated separately; 
extrapolating toxicity (or nontoxicity) by categorizing compound mixtures and making 
generalizations about classes of compounds (as is the case with fullerenes) with many different 
isomers is not acceptable to the FDA. A fundamental understanding of basic chemistry reveals 
that even extremely similar molecules can have different biologic activities. There are many 
examples where two isomers that are very similar have completely different biological behavior. 
For example, the tragedy of the drug thalidomide, where one isoform was an effective sedative 
and the mirror image isoform was teratogenic (resulting in fetal defects), changed the face of 
drug testing. It is important to note that pristine nonfunctionalized fullerenes behave significantly 
differently to their water-soluble functionalized counterparts, furthermore each variation in 
fullerene functionalization should be treated and evaluated as a separate entity. This applies to 
the studies with fullerenes, where even extremely small changes in the core fullerene structure 
(through the addition of side-chain moieties) can result in the FD having completely different 
biological properties. Several laboratories have demonstrated this repeatedly, which highlights 
the difficulty in interpreting data gathered from extrapolating findings between even very similar 
compounds. 
Complicating the task of bringing FDs to the marketplace is the fact that the FDA does not have 
specific guidelines for products containing nanoscale materials. A report issued by the 
FDA Nanotechnology Task Force (July 2007) recommends guidance by various centers within 
the FDA for industries working with nanomaterials [202] . Unlike 'standard' drug products, it is 
increasingly evident that at least in the area of characterization of nanomaterials used in drug 
products different standards apply. Applying small molecule principles and methodologies to 
nanomaterials cannot be extrapolated in biological settings. The study stressed that 
biodistribution analysis should be at the core of any evaluation of products containing 
nanomaterials. These biodistribution studies, as recommended by the FDA [202] , provide 
valuable information on where the nanoparticles are traveling and possibly accumulating, 
therefore, subjecting those sites to increased likelihood of toxicological effects. It was also 
stressed in the 2007 report that most studies (using nanomaterials) are limited in that they are 
short-term and might leave long-term effects unevaluated, especially because the long-term 
toxicity and effects for most nanoscale materials remain unknown. Furthermore, appropriate end 
points for in vitro assays are seen to be difficult to determine, as single cell types are often not 
sufficient for evaluation on the function or health of organs or tissues that are made up of 
multiple cell types, given that FDs are exposed to numerous types of tissues in the body. The 
major recommendation from the reports was that nanoscale materials be characterized with 
respect to size (surface area and size distribution), chemical composition (i.e., purity and 
crystallinity), surface structure (e.g., surface reactivity, surface groups and coatings), solubility, 
shape and aggregation. The protocols developed at the National Cancer Institute's, 
Nanotechnology Characterization Laboratories (MD, USA) was recommended as being very 
useful in helping to characterize nanoscale materials, and to develop standards and standardized 
methods for measuring nanoscale materials [203] . 
At present, it is difficult to make conclusions on the absorption, distribution, metabolism and 
excretion profile of the many types of carbon nanomaterials presently being investigated: carbon 
nanotubes; nanohorns; graphene; fullerenes; and derivatives of each of these nanomaterials. This 
is primarily due to the relative infancy of the field and limited research on the long-term effects 
of fullerenes on biological systems. However, several studies have been conducted assessing the 
elimination of fullerenes from the body [19,95] . Researchers have concluded that there is limited 
absorption of fullerenes following both intravenous and oral exposure in rats. In general, 
elimination was rapid from the body via feces and urine [19,95] . Furthermore, several 
experimental studies revealed that mice treated with excessive dosages (2000 mg/kg) of 
fullerenes have shown no overt toxicity [96,97] . In fact, some studies have shown that fullerene 
treatment in mice and rats can improve cognitive function and extend lifespan by 11% (in the 
mouse model) and 90% (in the rat model) [17,18] . Clearly contrasting results and limited long-
term data need to be addressed and efforts on creating reliable, reproducible results are still 
required for successful translation of these molecules into human systems. Focusing research to 
clarify chronic exposure to these materials, as well as identification of genotoxicity, 
carcinogenicity and reproductive toxicity will be paramount for encouraging fullerene studies in 
biological systems. Certainly, each carbon nanomaterial and specific derivatives should be 
carefully evaluated and characterized individually, as these materials exist in a variety of forms 
(e.g., carbon structure, carbon number, surface modification, charge, size, aggregation and 
degree of functionality). The extrapolation of results across such broad classes is not sufficient in 
characterizing the toxicity profiles of these molecules. Future research should be aimed at 
devising appropriate testing strategies to evaluate risk and toxicity profiles that do not generalize 
carbon nanoparticles as one, but rather evaluate each class individually. 
Conclusion & future perspective 
Fullerenes and their unique properties can be beneficial to many modern medical applications; as 
they are composed entirely of carbon in a hollow sphere (without requiring a toxic metal 
catalyst), their functionalization (with chemicals to increase their hydrophilicity) or 
encapsulation (in carriers, i.e., as liposomes) allows for easy solubility in biologically suitable 
aqueous media. The innate properties of fullerenes render high antioxidant capacity at extremely 
small sizes that can be functionalized or tailored to accommodate a broad range of diagnostic and 
therapeutic applications. Recent developments and future research in the fullerene field could 
reveal numerous commercial applications spanning a broad spectrum: antiviral; anticancer; 
photosensitizers; antioxidant activity; drug delivery and gene therapy; and highly sensitive-
targeted diagnostic applications. 
Current research in fullerenes could create significant strides in slowing or suppressing the 
progression of HIV infection to AIDS [98-100] . Mechanistically, their success as a potential 
antiviral application is based on the compounds unique geometry and high antioxidant activity. 
The compounds are capable of complexing and inhibiting the HIV protease with a relatively high 
structure-activity relationship [98] . The fullerenes can spatially bind in the cavity (10 Å 
approximate diameter) regions of HIV protease tightly and prevent the release of water, 
subsequently inhibiting the active regions of the protease [101] . The fullerenes strong affinity to 
bind to the enzymes active site results in significant inhibition of viral replication [99,102] . 
Fullerenes are also capable of being photoexcited and have, thus, been exploited as 
photosensitizers, whereby fullerenes can be conjugated with high affinity to specific proteins and 
nucleic acids. The photoirradiated fullerene is excited from its ground state and converted back 
via intersystem crossing, creating a highly toxic singlet oxygen species. Researchers have 
demonstrated that using photodynamic therapy, fullerenes could photosensitize specifically 
targeted cells, which could rapidly reduce cell viability [103] . This technique has also been 
modified to a theranostic approach utilizing gadolinium-containing endohedral fullerenes to 
selectively target, photosensitize and image tumor reduction over time [104] . 
The potential for using fullerene-based medicines is substantial but concerns of toxicity have 
slowed the initial enthusiasm that surrounded their discovery. Only those studies using well-
characterized, single species, 'lead candidate' fullerene formulations can provide meaningful 
information regarding potential toxicological effects. Such studies are needed as the state of 
research today with fullerenes is shaped by studies such as these that address the observation 
"that extrapolation across similar nanoparticles will be dependent upon surface chemistry and 
concentration which may affect the degree of agglomeration and thus biological effects" [105] . 
Thus, more thorough studies will serve as a building block in developing a database that links 
surface functionalization chemistry of fullerene compounds to biological function. Significant 
strides have been made throughout the last decade to help propel fullerenes as a functional 
platform to help solve many modern medical limitations. However, the translation of successful 
research into market application will require more work to better understand uptake, 
biodistribution, absorption, lifetime, excretion and, ultimately, consumer safety of these 
nanostructures. 
The unique physical and chemistry properties, the decrease in production cost, increased 
scalability and broad range of potential medical applications have stimulated a lot of research 
within the industry. While initial toxicity concerns stalled progress, recent studies have shown 
limited evidence of any toxicity associated with these novel nanomaterials. In time the fullerene 
field will make strides in penetrating industry, but only when more thorough characterization and 
sufficient research is accomplished to address long-term, reproducible toxicological data will this 
fascinating class of molecules bring advances to modern medicine. 
Executive summary 
Fullerenes as therapeutics 
* Specifically engineered fullerene derivatives (FDs) are taken up and can stabilize human mast 
cells by preventing the release of proinflammatory mediators. 
* FDs have the potential to become novel therapeutics for the treatment of asthma, illustrated 
through a mechanism involving the dampening of eosinophilia and cytokine levels, reducing 
airway hyper-responsiveness and upregulating eicosanoids. 
* FD-treated mice demonstrated a significant reduction in both the clinical indices as well as 
ankle swelling measurements. 
* FDs reduce the clinical scores associated with multiple sclerosis in the experimental allergic 
encephalomyelitis model. 
* Rationally designed fullerene compounds may be used as a platform for new areas of 
therapeutic research for those diseases influenced by mast cell mediators. 
Fullerenes as diagnostics 
* Gadolinium-containing fullerenes can serve as a platform for developing future biomarker-
targeting contrast agents. 
* Gadolinium endohedral fullerene-based MRI contrast agents can be functionalized to 
specifically target atherosclerotic plaques. 
Fullerenes as theranostics 
* Specifically engineered gadolinium endohedral fullerene MRI contrast agents can cross the 
blood-brain barrier to selectively target and deliver a therapeutic payload to cancerous 
glioblastoma cells. 
Fullerene toxicity: is there concern? 
* Studies on the toxicity of FDs have produced conflicting results in the scientific community; 
often experimental results are extrapolated across a diverse family of carbon-based 
nanomaterials. 
* Future research should be aimed at devising appropriate testing strategies to evaluate risk and 
toxicity profiles that do not generalize nanoparticles as one class, but rather evaluate each class 
individually. 
CAPTION(S): 
Figure 1. Representative fullerene structures. 
(A) Empty cage C60 fullerene, (B) empty cage C70 fullerene and (C) gadolinium-enclosed 
C80 endohedral fullerene. 
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